Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 2/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13540002 | 0.85 | — | — | |
| SCHEMBL124942 | 0.83 | ALDH1A1 (0.36) | MEN1GAAKMT2ASMN1; SMN2 | |
| SCHEMBL7750328 | 0.81 | ALDH1A1 (0.32) | GAA | |
| SCHEMBL19858951 | 0.80 | NPC1 (0.30) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL8872368 | 0.79 | — | — | |
| SCHEMBL1305300 | 0.76 | SLC1A2 (0.35) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL19204143 | 0.75 | ALDH1A1 (0.33) | MEN1GAAKMT2ASMN1; SMN2 | |
| SCHEMBL9472675 | 0.74 | THRB (0.35) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL3402119 | 0.74 | SLC1A3 (0.33) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL11436394 | 0.73 | TDP1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118191196-A | Method for measuring related substances of 4-chloropyrrolopyrimidine by gas chromatography | 湖北丽益医药科技有限公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-109563098-A | The method for preparing chloro- 7H- pyrrolo- [2,3-d] pyrimidine of 4- | 斯福瑞（南通）制药有限公司 | 2019-04-02 | — | — | CN | disclosed |
| EP-1540013-B1 | EVOLVING NEW MOLECULAR FUNCTION | HARVARD COLLEGE (US) | 2015-07-08 | — | — | EP | disclosed |
| EP-2758402-A1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | Pfizer Inc (US) | 2014-07-30 | — | — | EP | disclosed |
| EP-1423400-B2 | EVOLVING NEW MOLECULAR FUNCTION | HARVARD COLLEGE (US) | 2013-05-22 | — | — | EP | disclosed |
| WO-2013042006-A1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | PFIZER INC. (US) | 2013-03-28 | — | — | WO | disclosed |
| US-20120165228-A1 | EVOLVING NEW MOLECULAR FUNCTION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2012-06-28 | — | — | US | disclosed |
| US-8206914-B2 | Evolving new molecular function | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-06-26 | — | — | US | disclosed |
| US-7998904-B2 | Libraries of oligonucleotides created by genetic engineering | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-08-16 | — | — | US | disclosed |
| US-20110190141-A1 | Evolving New Molecular Function | PRESIDENT AND FELLOWS OF HAVARD COLLEGE (US) | 2011-08-04 | — | — | US | disclosed |
| US-20040180412-A1 | Evolving new molecular function | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2004-09-16 | — | — | US | disclosed |
| EP-1423400-A2 | EVOLVING NEW MOLECULAR FUNCTION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2004-06-02 | — | — | EP | disclosed |
| WO-2004016767-A2 | EVOLVING NEW MOLECULAR FUNCTION | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2004-02-26 | — | — | WO | disclosed |
| US-20030113738-A1 | Evolving new molecular function | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2003-06-19 | — | — | US | disclosed |
| WO-2002074929-A2 | EVOLVING NEW MOLECULAR FUNCTION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2002-09-26 | — | — | WO | disclosed |
| EP-0923287-A4 | NONCLASSICAL PYRROLO 2,3-D]PYRIMIDINE ANTIFOLATES | LILLY CO ELI (US) | 2001-08-01 | — | — | EP | disclosed |
| EP-0923287-A1 | NONCLASSICAL PYRROLO 2,3-D]PYRIMIDINE ANTIFOLATES | ELI LILLY AND COMPANY (US) | 1999-06-23 | — | — | EP | disclosed |
| US-5753664-A | ANTITUMOR AGENTS, PYRIMIDONES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-05-19 | — | — | US | disclosed |
| WO-1998008382-A1 | NONCLASSICAL PYRROLO[2,3-D]PYRIMIDINE ANTIFOLATES | ELI LILLY AND COMPANY (US) | 1998-03-05 | — | — | WO | disclosed |
| US-4218515-A | FOR FLOOR COVERINGS | HECKLES JOHN S | 1980-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165228-A1 | EVOLVING NEW MOLECULAR FUNCTION | POLI, PCNA, POLK | SLC1A3 4702/4885SLC1A2 4784/4885SLC1A1 4628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.